LB-100
In human trialsMeasured in people, not heightBy injectionSmall molecule
An experimental cancer drug that stops NPR2, the receptor CNP works through, being switched off.
An experimental cancer compound, used here as a phosphatase inhibitor. CNP activation of NPR2 requires the receptor to be phosphorylated on multiple serines and threonines, so FGF-induced dephosphorylation lowers cGMP and opposes bone growth; this counteracts that step.
Risks. In its first cancer trial in adults it could strain the kidneys, and about one patient in five had a severe side effect that may have been the drug. Nobody has tested it for growth.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.